Literature DB >> 19693506

Nephrogenic systemic fibrosis: an unusual scleroderma-like fibrosing disorder.

Eugenia Rota1, Maria Gabriella Nallino, Serena Bainotti, Marco Formica.   

Abstract

Nephrogenic systemic fibrosis (NSF) is a fibrosing disorder, recently described in patients with advanced chronic kidney disease, usually after exposure to gadolinium (Gd)-based contrast agents, characterized by progressive fibrotic involvement mainly of the skin. At clinical examination, the cutaneous findings of NSF may partly resemble those of systemic sclerosis. However, the different topographic distribution of the skin thickening and hardening, usually involving the limbs and trunk, whilst sparing the face, the lack of serologic abnormalities and the distinctive histopathological findings allow this new disease entity to be distinguished from systemic sclerosis and other scleroderma-like fibrosing disorders (scleromyxedema, scleredema, eosinophilic fasciitis, etc.). Herein, we describe what, to best of our knowledge, is the first, biopsy proven, Italian case of NSF, which highlights the issue of the differential diagnosis between NSF and scleroderma-like fibrosing disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19693506     DOI: 10.1007/s00296-009-1083-4

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  15 in total

Review 1.  Nephrogenic fibrosing dermopathy: the first 6 years.

Authors:  Shawn E Cowper
Journal:  Curr Opin Rheumatol       Date:  2003-11       Impact factor: 5.006

2.  Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?

Authors:  Thomas Grobner
Journal:  Nephrol Dial Transplant       Date:  2006-01-23       Impact factor: 5.992

3.  Nephrogenic systemic fibrosis--the need for a multidisciplinary approach.

Authors:  Joëlle L Nortier; Véronique del Marmol
Journal:  Nephrol Dial Transplant       Date:  2007-07-07       Impact factor: 5.992

4.  Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy.

Authors:  Shawn E Cowper
Journal:  Am J Kidney Dis       Date:  2005-10       Impact factor: 8.860

5.  Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis.

Authors:  Whitney A High; Reed A Ayers; John Chandler; Gary Zito; Shawn E Cowper
Journal:  J Am Acad Dermatol       Date:  2006-11-09       Impact factor: 11.527

6.  Nephrogenic fibrosing dermopathy, a new mimicker of systemic sclerosis.

Authors:  Angele Dupont; Vikas Majithia; Shariq Ahmad; Robert McMurray
Journal:  Am J Med Sci       Date:  2005-10       Impact factor: 2.378

Review 7.  New insights into nephrogenic systemic fibrosis.

Authors:  Sundararaman Swaminathan; Sudhir V Shah
Journal:  J Am Soc Nephrol       Date:  2007-09-12       Impact factor: 10.121

Review 8.  What nephrologists need to know about gadolinium.

Authors:  Jeffrey G Penfield; Robert F Reilly
Journal:  Nat Clin Pract Nephrol       Date:  2007-12

Review 9.  Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis.

Authors:  Amy S Peak; Amy Sheller
Journal:  Ann Pharmacother       Date:  2007-08-07       Impact factor: 3.154

Review 10.  Scleroderma-like fibrosing disorders.

Authors:  Francesco Boin; Laura K Hummers
Journal:  Rheum Dis Clin North Am       Date:  2008-02       Impact factor: 2.670

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.